These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 24697244)
1. Indirubin core structure of glycogen synthase kinase-3 inhibitors as novel chemotype for intervention with 5-lipoxygenase. Pergola C; Gaboriaud-Kolar N; Jestädt N; König S; Kritsanida M; Schaible AM; Li H; Garscha U; Weinigel C; Barz D; Albring KF; Huber O; Skaltsounis AL; Werz O J Med Chem; 2014 May; 57(9):3715-23. PubMed ID: 24697244 [TBL] [Abstract][Full Text] [Related]
2. Bromo-substituted indirubins for inhibition of protein kinase-mediated signalling involved in inflammatory mediator release in human monocytes. Bachmann V; Schädel P; Westhoff J; Perić M; Schömberg F; Skaltsounis AL; Höppener S; Pantsar T; Fischer D; Vilotijević I; Werz O Bioorg Chem; 2024 Aug; 149():107470. PubMed ID: 38838619 [TBL] [Abstract][Full Text] [Related]
3. Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases. Polychronopoulos P; Magiatis P; Skaltsounis AL; Myrianthopoulos V; Mikros E; Tarricone A; Musacchio A; Roe SM; Pearl L; Leost M; Greengard P; Meijer L J Med Chem; 2004 Feb; 47(4):935-46. PubMed ID: 14761195 [TBL] [Abstract][Full Text] [Related]
4. The indirubin derivative 6-bromoindirubin-3'-glycerol-oxime ether (6BIGOE) potently modulates inflammatory cytokine and prostaglandin release from human monocytes through GSK-3 interference. Czapka A; König S; Pergola C; Grune C; Vougogiannopoulou K; Skaltsounis AL; Fischer D; Werz O Biochem Pharmacol; 2020 Oct; 180():114170. PubMed ID: 32710971 [TBL] [Abstract][Full Text] [Related]
5. Further studies on ethyl 5-hydroxy-indole-3-carboxylate scaffold: design, synthesis and evaluation of 2-phenylthiomethyl-indole derivatives as efficient inhibitors of human 5-lipoxygenase. Peduto A; Bruno F; Dehm F; Krauth V; de Caprariis P; Weinigel C; Barz D; Massa A; De Rosa M; Werz O; Filosa R Eur J Med Chem; 2014 Jun; 81():492-8. PubMed ID: 24871899 [TBL] [Abstract][Full Text] [Related]
6. Soluble 3',6-substituted indirubins with enhanced selectivity toward glycogen synthase kinase -3 alter circadian period. Vougogiannopoulou K; Ferandin Y; Bettayeb K; Myrianthopoulos V; Lozach O; Fan Y; Johnson CH; Magiatis P; Skaltsounis AL; Mikros E; Meijer L J Med Chem; 2008 Oct; 51(20):6421-31. PubMed ID: 18816110 [TBL] [Abstract][Full Text] [Related]
7. 6-Br-5methylindirubin-3'oxime (5-Me-6-BIO) targeting the leishmanial glycogen synthase kinase-3 (GSK-3) short form affects cell-cycle progression and induces apoptosis-like death: exploitation of GSK-3 for treating leishmaniasis. Xingi E; Smirlis D; Myrianthopoulos V; Magiatis P; Grant KM; Meijer L; Mikros E; Skaltsounis AL; Soteriadou K Int J Parasitol; 2009 Oct; 39(12):1289-303. PubMed ID: 19445946 [TBL] [Abstract][Full Text] [Related]
8. GSK-3-selective inhibitors derived from Tyrian purple indirubins. Meijer L; Skaltsounis AL; Magiatis P; Polychronopoulos P; Knockaert M; Leost M; Ryan XP; Vonica CA; Brivanlou A; Dajani R; Crovace C; Tarricone C; Musacchio A; Roe SM; Pearl L; Greengard P Chem Biol; 2003 Dec; 10(12):1255-66. PubMed ID: 14700633 [TBL] [Abstract][Full Text] [Related]
9. An inhibitor-driven study for enhancing the selectivity of indirubin derivatives towards leishmanial Glycogen Synthase Kinase-3 over leishmanial cdc2-related protein kinase 3. Efstathiou A; Gaboriaud-Kolar N; Smirlis D; Myrianthopoulos V; Vougogiannopoulou K; Alexandratos A; Kritsanida M; Mikros E; Soteriadou K; Skaltsounis AL Parasit Vectors; 2014 May; 7():234. PubMed ID: 24886176 [TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of a class of 5-benzylidene-2-phenyl-thiazolinones as potent 5-lipoxygenase inhibitors. Barzen S; Rödl CB; Lill A; Steinhilber D; Stark H; Hofmann B Bioorg Med Chem; 2012 Jun; 20(11):3575-83. PubMed ID: 22551629 [TBL] [Abstract][Full Text] [Related]
11. Synthesis of novel 5-substituted indirubins as protein kinases inhibitors. Beauchard A; Ferandin Y; Frère S; Lozach O; Blairvacq M; Meijer L; Thiéry V; Besson T Bioorg Med Chem; 2006 Sep; 14(18):6434-43. PubMed ID: 16759872 [TBL] [Abstract][Full Text] [Related]
12. N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular efficacy. Tavares FX; Boucheron JA; Dickerson SH; Griffin RJ; Preugschat F; Thomson SA; Wang TY; Zhou HQ J Med Chem; 2004 Sep; 47(19):4716-30. PubMed ID: 15341487 [TBL] [Abstract][Full Text] [Related]
13. An evaluation of indirubin analogues as phosphorylase kinase inhibitors. Begum J; Skamnaki VT; Moffatt C; Bischler N; Sarrou J; Skaltsounis AL; Leonidas DD; Oikonomakos NG; Hayes JM J Mol Graph Model; 2015 Sep; 61():231-42. PubMed ID: 26364215 [TBL] [Abstract][Full Text] [Related]
14. Novel 9-oxo-thiazolo[5,4-f]quinazoline-2-carbonitrile derivatives as dual cyclin-dependent kinase 1 (CDK1)/glycogen synthase kinase-3 (GSK-3) inhibitors: synthesis, biological evaluation and molecular modeling studies. Logé C; Testard A; Thiéry V; Lozach O; Blairvacq M; Robert JM; Meijer L; Besson T Eur J Med Chem; 2008 Jul; 43(7):1469-77. PubMed ID: 17981370 [TBL] [Abstract][Full Text] [Related]
15. Biosynthesis of new indigoid inhibitors of protein kinases using recombinant cytochrome P450 2A6. Wu ZL; Aryal P; Lozach O; Meijer L; Guengerich FP Chem Biodivers; 2005 Jan; 2(1):51-65. PubMed ID: 17191919 [TBL] [Abstract][Full Text] [Related]
16. 3D QSAR for GSK-3beta inhibition by indirubin analogues. Zhang N; Jiang Y; Zou J; Zhang B; Jin H; Wang Y; Yu Q Eur J Med Chem; 2006 Mar; 41(3):373-8. PubMed ID: 16442187 [TBL] [Abstract][Full Text] [Related]